Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

Completed · Phase 2

Conditions studied: Carcinoma of Unknown Primary

In brief

RATIONALE: Drugs used in chemotherapy such as gemcitabine and irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan works in treating patients with cancer of unknown primary origin.

Key facts

Study ID

NCT00066781

Run by

Alliance for Clinical Trials in Oncology

People needed

31

Starts

2004-02-01

Expected to finish

2009-03-01

Last updated by the study team

2017-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mercy Cancer Center at Mercy Medical Center - North Iowa — Mason City, Iowa, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Cancer Resource Center - Lincoln — Lincoln, Nebraska, United States
• CCOP - Missouri Valley Cancer Consortium — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.